Home Blog of Signal Transduction PI3K/Akt/mTOR mTOR

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

mTOR

CCL17 exerts neuroprotection through activation of CCR4/mTORC2 axis in microglia after subarachnoid haemorrhage in rats

134 views | Jan 26 2024

This study elucidates that CCL17 activates the CCR4/mTORC2 axis in microglia, promoting M2-like polarization and significantly ameliorating neurological deficits after subarachnoid hemorrhage. [Read the Full Post]

PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, relieves airway hyperresponsiveness, mucus hypersecretion and inflammation in a murine asthma model

343 views | Jan 14 2024

PP121, a dual tyrosine and phosphoinositide kinase inhibitor, demonstrates promising anti-contractile and anti-inflammatory effects in asthma treatment, suggesting its potential as a novel therapeutic compound for managing the condition. [Read the Full Post]

Percutaneous coronary intervention with ridaforolimus-eluting stents in long lesions: the BIONICS 38 mm prospective trial

308 views | Jan 08 2024

The study evaluating the 38 mm ridaforolimus-eluting stent in percutaneous coronary intervention for long lesions demonstrated high efficacy, low rates of major adverse cardiovascular events, and successful treatment outcomes, supporting its safety and effectiveness in this patient group. [Read the Full Post]

Quantitative Proteomics Characterization of the Effect and Mechanism of Trichostatin A on the Hippocampus of Type II Diabetic Mice

149 views | Jan 03 2024

The study demonstrates Trichostatin A's potential in improving cognitive function in diabetic encephalopathy by modulating key proteins and pathways, highlighting its promise as a therapeutic intervention and suggesting potential similar and ancillary drugs for treatment. [Read the Full Post]

Pharmacological effects of mTORC1/C2 inhibitor in a preclinical model of NASH progression

118 views | Dec 13 2023

The study demonstrates that the mTORC1/C2 inhibitor Ku-0063794 (KU) effectively alleviates NASH-related hepatotoxicity, reduces oxidative stress, modulates gene expression, and decreases inflammation in a mouse model, highlighting its potential as a therapeutic candidate for non-alcoholic steatohepatitis. [Read the Full Post]

Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

343 views | Dec 13 2023

In summary, the study reveals that inhibiting phosphorylated S6 ribosomal protein, a marker of mTORC1 activity, suppresses glucose metabolism pathways and reduces cell proliferation, suggesting mTORC1 as a potential therapeutic target in distal cholangiocarcinoma. [Read the Full Post]

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

489 views | Dec 07 2023

The study demonstrates that ABTL0812, an oral anticancer compound, inhibits GBM cell proliferation, reverses proneural to mesenchymal transition, induces cell differentiation, and promotes autophagy-mediated cell death, providing compelling evidence for its potential as a novel therapy, either alone or in combination with standard treatments, for glioblastoma multiforme. [Read the Full Post]

Reconstructing the immunosenescence core pathway reveals global characteristics in pan-cancer

150 views | Nov 20 2023

Your study systematically analyzed multi-omics data from 12,836 tumor samples, revealing disordered immunosenescence pathways across cancer types, emphasizing the pan-cancer activation of immunosenescence pathways, and identifying the MTOR gene as a potential sex-specific immunosenescence biomarker in head and neck squamous carcinoma, suggesting OSI-027 as a promising sex-specific drug. [Read the Full Post]

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

218 views | Nov 13 2023

The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that employs genomic profiling and adaptive randomization to evaluate novel therapies for glioblastoma, with abemaciclib and neratinib showing improved progression-free survival compared to the control arm, although none of the experimental therapies demonstrated a significant overall survival benefit. [Read the Full Post]

Production of highly pure R,R-2,3-butanediol for biological plant growth promoting agent using carbon feeding control of Paenibacillus polymyxa MDBDO

337 views | Nov 03 2023

The study demonstrates the potential of Paenibacillus polymyxa MDBDO as a biological plant growth promoting agent and outlines a fermentation strategy for the production of highly pure R,R-2,3-butanediol (R,R-2,3-BDO) at high concentrations, which significantly stimulates the growth of soybean and strawberry seedlings. [Read the Full Post]